5′-Modifications improve potency and efficacy of DNA donors for precision genome editing

Nuclease-directed genome editing is a powerful tool for investigating physiology and has great promise as a therapeutic approach to correct mutations that cause disease. In its most precise form, genome editing can use cellular homology-directed repair (HDR) pathways to insert information from an ex...

Full description

Saved in:
Bibliographic Details
Published ineLife Vol. 10
Main Authors Ghanta, Krishna S, Chen, Zexiang, Mir, Aamir, Dokshin, Gregoriy A, Krishnamurthy, Pranathi M, Yoon, Yeonsoo, Gallant, Judith, Xu, Ping, Zhang, Xiao-Ou, Ozturk, Ahmet Rasit, Shin, Masahiro, Idrizi, Feston, Liu, Pengpeng, Gneid, Hassan, Edraki, Alireza, Lawson, Nathan D, Rivera-Pérez, Jaime A, Sontheimer, Erik J, Watts, Jonathan K, Mello, Craig C
Format Journal Article
LanguageEnglish
Published England eLife Science Publications, Ltd 19.10.2021
eLife Sciences Publications Ltd
eLife Sciences Publications, Ltd
Subjects
Online AccessGet full text
ISSN2050-084X
2050-084X
DOI10.7554/eLife.72216

Cover

More Information
Summary:Nuclease-directed genome editing is a powerful tool for investigating physiology and has great promise as a therapeutic approach to correct mutations that cause disease. In its most precise form, genome editing can use cellular homology-directed repair (HDR) pathways to insert information from an exogenously supplied DNA-repair template (donor) directly into a targeted genomic location. Unfortunately, particularly for long insertions, toxicity and delivery considerations associated with repair template DNA can limit HDR efficacy. Here, we explore chemical modifications to both double-stranded and single-stranded DNA-repair templates. We describe 5′-terminal modifications, including in its simplest form the incorporation of triethylene glycol (TEG) moieties, that consistently increase the frequency of precision editing in the germlines of three animal models ( Caenorhabditis elegans , zebrafish, mice) and in cultured human cells.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors also contributed equally to this work.
Tessera Therapeutics, Cambridge, United States.
Vertex Pharmaceuticals, Boston, United States.
Bristol Myer Squibb, Cambridge, United States.
ISSN:2050-084X
2050-084X
DOI:10.7554/eLife.72216